Condition: Lymphoma · Follicular Lymphoma · Lymphoma,Non-Hodgkin · Sponsor: Beth Israel Deaconess Medical Center
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
This description comes directly from the study's public registry record.
Gottfried von Keudell, MD, PhD · 617-667-9920 · gkeudell@bidmc.harvard.edu
Dea Hunsicker, MSN · 617-667-9920 · dhunsick@bidmc.harvard.edu
Always discuss trial participation with your own doctor first.
| Stanford | Stanford, California, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06510361